Evidence map›Paper›PMID 25794163›Full record

ArticlePloS one2015

Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy.

Suad Kapetanovic, Lisa Aaron, Grace Montepiedra, Patricia Anthony, Kasalyn Thuvamontolrat, Savita Pahwa, Sandra Burchett, Adriana Weinberg, Andrea Kovacs, Pediatric AIDS Clinical Trials Group Protocol 366

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Cytomegalovirus and paediatric HIV infection.Journal of virus eradication · 2016
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Suad KapetanovicNational Institutes of Health, National Institute of Mental Health, Bethesda MD, United States of America.
Lisa AaronCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston MA, United States of America.
Grace MontepiedraCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston MA, United States of America.
Patricia AnthonyMaternal, Child and Adolescent Center for Infectious Diseases and Virology, University of Southern California Keck School of Medicine, Los Angeles CA, United States of America.
Kasalyn ThuvamontolratMaternal, Child and Adolescent Center for Infectious Diseases and Virology, University of Southern California Keck School of Medicine, Los Angeles CA, United States of America.
Savita PahwaUniversity of Miami Miller School of Medicine, Miami FL, United States of America.
Sandra BurchettChildren's Hospital Boston and Harvard Medical School, Boston MA, United States of America.
Adriana WeinbergUniversity of Colorado Denver, Denver CO, United States of America.
Andrea KovacsMaternal, Child and Adolescent Center for Infectious Diseases and Virology, University of Southern California Keck School of Medicine, Los Angeles CA, United States of America.
Pediatric AIDS Clinical Trials Group Protocol 366
University of Southern California · USCancer Research And Biostatistics · USHarvard University · USNational Institutes of Health · USUniversity of Denver · USUniversity of Miami · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
University of Puerto Rico Clinical Trials UnitUM1AI069415 · NIAID · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FEBO, IRMA LUZ, SANTANA-BAGUR, JORGE L. · 2012 to 2021
$15.2M
Miami Treatment and Prevention Clinical Trials Unit (CTU)UM1AI069477 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI JAYAWEERA, DUSHYANTHA, SCOTT, GWENDOLYN BARBARA · 2012 to 2020
$9.2M
Intramural NIH HHSNCATS NIH HHS UL1 TR001082NCRR NIH HHS UL1 RR025758NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1AI068632NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069477NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1AI106716
6 · The paper itself

Abstract

backgroundWe examined the effect of cytomegalovirus (CMV) co-infection and viremia on reconstitution of selected CD4+ and CD8+ T-cell subsets in perinatally HIV-infected (PHIV+) children ≥ 1-year old who participated in a partially randomized, open-label, 96-week combination antiretroviral therapy (cART)-algorithm study.

methodsParticipants were categorized as CMV-naïve, CMV-positive (CMV+) viremic, and CMV+ aviremic, based on blood, urine, or throat culture, CMV IgG and DNA polymerase chain reaction measured at baseline. At weeks 0, 12, 20 and 40, T-cell subsets including naïve (CD62L+CD45RA+; CD95-CD28+), activated (CD38+HLA-DR+) and terminally differentiated (CD62L-CD45RA+; CD95+CD28-) CD4+ and CD8+ T-cells were measured by flow cytometry.

resultsOf the 107 participants included in the analysis, 14% were CMV+ viremic; 49% CMV+ aviremic; 37% CMV-naïve. In longitudinal adjusted models, compared with CMV+ status, baseline CMV-naïve status was significantly associated with faster recovery of CD8+CD62L+CD45RA+% and CD8+CD95-CD28+% and faster decrease of CD8+CD95+CD28-%, independent of HIV VL response to treatment, cART regimen and baseline CD4%. Surprisingly, CMV status did not have a significant impact on longitudinal trends in CD8+CD38+HLA-DR+%. CMV status did not have a significant impact on any CD4+ T-cell subsets.

conclusionsIn this cohort of PHIV+ children, the normalization of naïve and terminally differentiated CD8+ T-cell subsets in response to cART was detrimentally affected by the presence of CMV co-infection. These findings may have implications for adjunctive treatment strategies targeting CMV co-infection in PHIV+ children, especially those that are now adults or reaching young adulthood and may have accelerated immunologic aging, increased opportunistic infections and aging diseases of the immune system.

Indexed as

Antiretroviral Therapy, Highly ActiveCoinfectionLymphocyte CountAdolescentAntigens, CDCaliforniaChildChild, PreschoolCytomegalovirus InfectionsFemaleHIV InfectionsHumansImmunity, CellularImmunophenotypingInfantLymphocyte ActivationAntigens, CD

Identifiers

PMID25794163
PMCPMC4368806
OpenAlexW2046478217

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.